Goodwin Advises Kardigan on Closing of $460 Million Upsized Initial Public Offering

The Life Sciences team advised Kardigan, Inc., (“Kardigan”) on the closing of its initial public offering of an aggregate 28,750,000 shares of common stock at a public offering price of $16.00 per share, which includes 3,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds from the offering were $460 million before deducting underwriting discounts and commissions and other offering expenses. The shares commenced trading on the Nasdaq Global Market on June 18, 2026, under the ticker symbol “KARD.”

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. The company is based in South San Francisco, California, and Princeton, New Jersey.

The Goodwin team was led by Mitch Bloom, Ben Marsh, Janet Hsueh, Eunice Chang, Kelly Deas, Nikhil Shiva, Julia Shaver, and Rachel Staats, and included Julie Tibbets, Steve Tjoe, Matt Wetzel, Paul Jin, Ortal Ben Aharon, Olivia Uitto, Sarah Bock, Austin Fahnestock, Brian Mukherjee, Emily Beman, Omer Tene, and Cody Foster, with invaluable assistance from Rob Dzialo.

For more information on the deal, please read the press release and coverage in Endpoints News.